Full Length Research Paper
References
Acar JF, Goldstein FW (1997). "Trends in bacterial resistance to fluoroquinolones," Clin. Infect. Dis. 24(1):S67–S73. Crossref |
||||
Adam HJ, Hoban DJ, Gin AS, Zhanel GG (2009). "Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006," Int. J. Antimicrob. Agents 34(1):82-5. Crossref |
||||
AMR Trends Report Epidemiological services (2009). British Columbia Centre for Disease Control, "Antimicrobial resistance trends in the province of British Columbia," AMR Trends Report. View | ||||
Azap OK, Arslan H, Serefhanog lu K, Colakog lu S, Erdogan H, Timurkaynak F, Senger SS (2010). "Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections," Clin. Microbiol. Infect. 16(2):147–151. Crossref |
||||
Bhanot SK, Singh M, Chatterjee NR (2001). The Chemical and Biological Aspects of Fluoroquinolones: Reality and Dreams. Current Pharmaceutical Design, 7:313-337. Crossref |
||||
Bhavnani SM, Hammel JP, Jones RN, Ambrose PG (2005). "Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States, "Diagnostic Microbiol. Infect. Dis. 51(1):31–37. Crossref |
||||
Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA, Jones RN (2000). "Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients," J. Clin. Microbiol. 38(5):1818–1822. Pubmed |
||||
Urban C, Naim R, Xilin Z, Noriel M, Sorana Segal-Maurer, Karl D, James JR (2001). "Fluoroquinolone resistant Streptococcus pneumoniae associated with levofloxacin therapy," J. Infect. Dis. 184(6):794–798. Crossref |
||||
Chen DK, McGeer A, De Azavedo JC, Low DE (1999). "Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada," New Engl. J. Med. 341(4):233–229. Crossref |
||||
Han C, Yang Y, Wang M, Wang A, Lu Q, Xu X, Wang C, Liu L, Deng Q, Shen X (2010). "The prevalence of plasmidmediated quinolone resistance determinants among clinical isolates of ESBL or AmpC-producing Escherichia coli from Chinese pediatric patients," Microbiol. Immunol. 54(3):123–128. Crossref |
||||
Chikwendu CI, Nwabueze RN, Anyanwu BN (2008). Antibiotic resistance profile of Escherichia coli from clinically healthy pigs and their commercial farm environments. Afr. J. Microbiol. Res. 2:12 – 17. | ||||
Clinical and Laboratory Standards Institute, CLSI (2006). Performance standards for antimicrobial susceptibility testing, 16th informational supplement. M100-S16, Vol. 26, No. 3, pp: 1–37. | ||||
Cowan SR, Stell KJ (1993). Manual for Identification of Medical Bacteria, pp. 140–143. 3rd Ed. Cambridge University Press, Uk. | ||||
Foroumadi A, Ghodshi S, Emani S, Najjari S, Samadi N, Ali Faramarzi M, Beikmohammadi L, Shirazi FH, Shafie A (2006). Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl) piperzine moiety. Bioorg. Med. Chem. Lett, 16:3499-3503. Crossref |
||||
Fuller JD, Low DE (2005). "A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance," Clin. Infect. Dis. 41(1):118–121. Crossref |
||||
Manno G, Cruciani M, Romano L, Scapolan S, Mentasti M, Lorini R, Minicucci L (2005). "Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre," Int. J. Antimicrobial Agents 25(3):193–197. Crossref |
||||
Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH (1999). "Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumonia in Hong Kong," Antimicrob. Agents Chemother. 43(5):1310–1313. Pubmed |
||||
Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF (2002). "Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States," Antimicrob. Agents Chemother. 46(8):2540–2545. Crossref |
||||
Lehn N, StöwerHoffmann J, Kott T, Strassner C, Wagner H, Krönke M, Schneider-Brachert W (1996). Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol. 34:597-602. Pubmed |
||||
Luzzaro F (2008). Fluoroquinolones and Gram-negative bacteria: antimicrobial activity and mechanisms of resistance. Le Infezioni in Medicina, 16(2):5–11. Pubmed |
||||
Morosini MI, Garc´Ä±a-Castillo M, Loza E, P´erez-V´azquez M, Baquero F, Cant´on R (2005), "Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips," J. Clin. Microbiol. 43(9):4480–4485. Crossref |
||||
Mulvey MR, Simor AE (2009). Antimicrobial resistance in hospitals: How concerned should we be? Can. Med. Assoc. J. 180: 408–415. Crossref |
||||
Naber KG, Schito G, Botto H, Palou J, Mazzei T (2008). "Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for Empiric Therapy. European Urology 54(5):1164–1178. Pubmed |
||||
Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H (2012). "French results of the ARESC Study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy," Medecine et Maladies Infect. 42(2):66–75 Crossref |
||||
Paterson DL (2004). "'Collateral damage"' from cephalosporin or quinolone antibiotic therapy," Clin. Infect. Dis. 38(4):S341–S345. Crossref |
||||
Pitt TL, Sparrow M, Warner M, Stefanidou M (2003). "Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents," Thorax, 58(9):794–796. Crossref |
||||
Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T (2011). "Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with communityacquired pneumonia despite high fluoroquinolone usage," Int. J. Med. Microbiol. 301(1):53–57. Crossref |
||||
Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN (2005). "Susceptibility patterns of Streptococcus pneumonia isolates in North America (2002–2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents," Int. J. Antimicrob. Agents 25(4):282–289. Crossref |
||||
Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE (2002). "Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia," New Engl J. Med. 346(10):747–750. Crossref |
||||
Schulin T (2002). "In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany," J. Antimicrob. Chemother. 49(2):403–406. Crossref |
||||
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A (2009). "The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections," Int. J. Antimicrob. Agents 34(5):407–413. Pubmed |
||||
Schwartz B, Bell DM, Hughes JM (1997). Preventing the emergence of antimicrobial resistance: A call for action by clinicians, public health officials and patients. JAMA, 278:944–945. Pubmed |
||||
Shindikar AV, Viswanthan CL (2005). Novel fluoroquinolones: design, synthesis and in vitro activity in mice against Mybacteririum tuberculosis H-37 Rv, Bioorg. Med. Chem. Lett. 15:1803-6. Pubmed |
||||
Sibi G, Devi AP, Fouzia K, Patil BR (2011). Prevalence, microbiologic profile of urinary tract infection and its treatment with trimethoprim in diabetic patients. Res. J. Microbiol. 6:543–551. Crossref |
||||
Smith DW (1999). Decreased antimicrobial resistance after changes in antibiotics use. Pharmacotherapy 19:129–132. Crossref |
||||
Strateva T, Petrova G, Perenovska P, Mitov I (2009), "Bulgarian cystic fibrosis Pseudomonas aeruginosa isolates: antimicrobial susceptibility and neuraminidase-encoding gene distribution," J. Med. Microbiol. 58(5):690–692. Crossref |
||||
Taddele MH, Rathore R, Dhama K (2012). Antibiogram assay of Salmonella gallinarum and other Salmonella enteric serovars of poultry origin in India. Asian J. Anim. Vet. Adv. 7:309–317. Crossref |
||||
Talah A, Gadad K (2006). Synthesis, antibacterial and antitubercular activities of some7-[4-(5-amino-[1, 3, 4] thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolonic derivatives. Eur. J. Med. Chem. 1-7. Pubmed | ||||
Truong QC, Gutmann L, Shlaes D, Moreau NJ (1995). New mutation in DNA gyrase of Escherichia coli conferring resistance to quinolones [abstract no. C61]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. | ||||
Wagenlehner FME, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, Kniehl E, Selbach I, Sester U, Vahlensieck W, Watermann D, Naber KG (2011). "National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients," Urologe A, 50(2):153–169. Crossref |
||||
Waites K, Brown S (2003). "Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001." Southern Med. J. 96(10):974–985. Pubmed |
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0